Olfactomedin-like 3
Olfactomedin-like protein 3 is a protein that in humans is encoded by the OLFML3 gene.[1] It has been shown to act as a proangiongenic factor in the tumor microenvironment, being released by endothelial cells and pericytes.[2]
References
- ↑ “Entrez Gene: OLFML3 olfactomedin-like 3”.
- ↑ Miljkovic-Licina, M.; Hammel, P.; Garrido-Urbani, S.; Lee, B. P.- L.; Meguenani, M.; Chaabane, C.; Bochaton-Piallat, M.-L.; Imhof, B. A. (20 September 2012). “Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage”. Molecular Cancer Therapeutics. 11 (12): 2588–2599. doi:10.1158/1535-7163.MCT-12-0245.
Further reading
- Maruyama K, Sugano S (1994). “Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides”. Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). “Construction and characterization of a full length-enriched and a 5′-end-enriched cDNA library”. Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Clark HF, Gurney AL, Abaya E, et al. (2003). “The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment”. Genome Res. 13 (10): 2265–70. doi:10.1101/gr.1293003. PMC 403697. PMID 12975309.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). “Complete sequencing and characterization of 21,243 full-length human cDNAs”. Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Zeng LC, Liu F, Zhang X, et al. (2004). “hOLF44, a secreted glycoprotein with distinct expression pattern, belongs to an uncharacterized olfactomedin-like subfamily newly identified by phylogenetic analysis”. FEBS Lett. 571 (1–3): 74–80. doi:10.1016/j.febslet.2004.06.059. PMID 15280020.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). “The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)”. Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Fautsch MP, Vrabel AM, Johnson DH (2006). “The identification of myocilin-associated proteins in the human trabecular meshwork”. Exp. Eye Res. 82 (6): 1046–52. doi:10.1016/j.exer.2005.09.016. PMID 16289162.
- Otsuki T, Ota T, Nishikawa T, et al. (2007). “Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries”. DNA Res. 12 (2): 117–26. doi:10.1093/dnares/12.2.117. PMID 16303743.
- Gregory SG, Barlow KF, McLay KE, et al. (2006). “The DNA sequence and biological annotation of human chromosome 1”. Nature. 441 (7091): 315–21. doi:10.1038/nature04727. PMID 16710414.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH